DayOne Catalyst Project: Oonida
One of the pillars of BaselArea.swiss’ DayOne (www.DayOne.swiss) strategy is to drive Catalyst projects – collaborative approaches to bottleneck issues in Healthcare innovation. These are “wicked problems” that can only be solved collaboratively. Therefore, Catalyst Projects focus on challenges to which it is difficult to find solutions within the current industry structures.
DayOne Catalyst project workshop (img: Frank Kumli)
The access to healthcare data is one of the best-known bottleneck issues in healthcare innovation and is being addressed by Oonida. The Basel based not-for-profit company is building a citizen centric platform where health data can be shared between patients and all relevant healthcare stakeholders. As a neutral steward OoNiDa aims to improve the efficiency within the ecosystem and overall population health by encouraging free flow of information in the health ecosystem so services and care can be delivered more efficiently and innovation can be stimulated.
New insights and connections
On behalf of OoNiDa DayOne brought together 15 volunteering healthcare innovators across industry and disciplines from the Basel ecosystem. During a full-day workshop at the DayOne Innovation Lab in the Technologiepark Basel, the OoNiDa management was able to validate and refine their business model and to come up with a minimal viable product that could be launched and tested in the local market.
“It is a unique experience for a startup in the very early stage like ours, to get access to some of the brightest minds in the Basel Healthcare Innovation Ecosystem. Not only did we gain new insights but could also make most valuable connections to future partners and customers of our platform”, stated Andy Bushell, Founder and CEO of OoNiDa.
… about the workshop with Oonida and about our Catalyst projects www.dayone.ch/projects.
If you or your organization would like to launch a Catalyst project, please contact email@example.com
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More